home / stock / aezs / aezs news


AEZS News and Press, Aeterna Zentaris Inc. From 01/20/22

Stock Information

Company Name: Aeterna Zentaris Inc.
Stock Symbol: AEZS
Market: NASDAQ
Website: zentaris.com

Menu

AEZS AEZS Quote AEZS Short AEZS News AEZS Articles AEZS Message Board
Get AEZS Alerts

News, Short Squeeze, Breakout and More Instantly...

AEZS - Aeterna Zentaris to Present at the Virtual Investor 2022 Top Picks Conference

– Live video webcast presentation on Wednesday, January 26 th at 9:00 AM ET CHARLESTON, S.C., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharma...

AEZS - JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th

- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast presentations of participating companies followed by interactive Q&A session - PITTSTOWN, NJ / ACCESSWIRE / January 12, 2022 / JTC Team ("JTC"), a fully integrate...

AEZS - Aeterna Zentaris to Present at the H.C. Wainwright BioConnect Conference

CHARLESTON, S.C., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic pr...

AEZS - Aeterna Zentaris names new finance chief

Aeterna Zentaris (NASDAQ:AEZS) appoints Giuliano La Fratta as Senior VP, CFO. Effective January 24th, 2022, Mr. La Fratta will be responsible for the finance-related leadership functions, succeeding Ms. Leslie Auld, the company’s current Senior VP, CFO. Ms...

AEZS - Aeterna Zentaris Appoints Giuliano La Fratta as Chief Financial Officer

– Well-established finance professional with over 20 years of experience gained in pharmaceutical, biopharma and professional services sectors TORONTO, ONTARIO, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna...

AEZS - Aeterna Zentaris revenue in-line

Aeterna Zentaris (NASDAQ:AEZS): Q3 Net Finance Income of $0.1M Revenue of $0.6M (+500.0% Y/Y) in-line. Press Release For further details see: Aeterna Zentaris revenue in-line

AEZS - Aeterna Zentaris Reports Third Quarter 2021 Financial Results and Provides Pipeline Program Updates

– Company continues to build strong developmental pipeline – S upported by solid cash position TORONTO, ONTARIO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “C...

AEZS - How Robots and A.I. are About To Change This $11 Trillion Industry Forever

TikTok’s nearly 700 million users seek medical advice from random individuals and charlatans, since anyone can claim to be a medical expert on this raging social media machine. Dr. Google is also working overtime, receiving more than one billion healthcare questions every day...

AEZS - Why A.I. Is About To Trigger The Next Great Medical Breakthrough

The healthcare industry is one of the fastest growing in the world, but today, it's seeing a major disruption. With everything from work meetings to family gatherings going digital since 2020, this mammoth $12 trillion industry is joining the new tech renaissance to deliver a much-neede...

AEZS - Should You Buy Aeterna Zentaris Under $1?

Drug development company Aeterna Zentaris (AEZS), specialized in oncology and endocrine, has made significant advancements in areas of unmet medical needs. But since its therapeutic and diagnostic products are still in their clinical and preclinical development stages, commercialization could...

Previous 10 Next 10